Clinical research participation FAQ

Start with an official registry such as ClinicalTrials.gov and with institutions or disease-specific research networks you can verify. Preserve the registry identifier and confirm local status. See how to find studies.

No. Registration requirements vary by study, jurisdiction, and timing. Ask for the protocol identifier, sponsor, reviewing IRB, conducting institution, and applicable registry. The absence of an NCT number is an unanswered verification question, not proof of fraud.

No. Overall and location-level status can differ, and records can lag local operations. Check Contacts and Locations, record the last-update date, and confirm the local cohort with the site.

No. OHRP describes consent (opens in a new tab) as an ongoing exchange of information. Ask questions before signing and whenever information changes.

Ask for time and a copy. Enrollment timing can constrain the decision window, yet the process must support voluntary understanding. Ask how questions are answered and whether remote or translated materials are available.

Tell the site the communication format, interpreter, physical access, technology, time, or companion support you need. Ask who arranges it and test the plan before consent or travel. Use the accessibility and caregiver guide.

Possibly. Randomized trials can assign placebo, standard care, active comparator, or another dose. Read every arm and ask for the assignment ratio.

No. IRB review is an important protection that evaluates risk, consent, and safeguards under applicable rules. Research retains uncertainty. Review the specific consent and your medical circumstances.

Final eligibility can depend on consented tests, records, protocol calculations, investigator judgment, cohort availability, and sponsor confirmation. Prescreening checks broad criteria.

Do not change treatment on your own. Ask the study investigator and your clinician whether a protocol washout is safe and appropriate for you.

Ask which records, dates, recipient, purpose, and secure method are required. Some studies need broad history. Others can answer an early question with a narrower record.

No reliable rule connects the headline amount to personal risk. Payment can reflect time, inconvenience, procedures, recruitment needs, or study design. Review risks and benefits separately.

For FDA-regulated research, FDA guidance (opens in a new tab) says payment should accrue as participation progresses and the entire amount should not depend on completion. A reasonable completion incentive can be reviewed separately. Ask for the approved schedule.

No. Access to treatment and financial responsibility are separate questions. Read who is billed, what qualifies, what insurance processes first, and which cost sharing remains. Use the injury and insurance guide.

It may, depending on the payment, jurisdiction, and your circumstances. Keep records and ask a qualified tax professional or benefits administrator. The research team can identify the payer and expected forms.

Participation is voluntary. Discuss safe stopping, product or device return, recommended follow-up, existing data, specimens, and accrued payment. See the withdrawal guide.

Use the participant-rights or IRB contact in the consent form. For symptoms, use the study’s clinical or after-hours contact. For emergencies, use local emergency services and follow the consent instructions.

Return depends on the protocol, test, and consent. Ask which results are clinical, research-only, incidental, urgent, individual, or aggregate. ClinicalTrials.gov may post summary results after the study.

Confirm the safety window, product or device return, accrued payment, data and specimen terms, transition to regular care, treatment assignment, and result path. Use the 20-point study closeout checklist.

Data already collected may remain for study integrity, safety, or legal duties. Future collection and optional follow-up may be handled separately. Ask what can still be stopped and what cannot be retrieved.